Helping projects
change the future
APPLY NOW

News

Primer Capital CEO at RBC Online Conference on Anti-crisis Business Solutions after COVID-19

17 April 2020

Anton Lavrentyev spoke at  the RBC-TV online conference dedicated to anti-crisis solutions for busines after COVID 19.

Primer Capital CEO at RBC Online Conference on Anti-crisis Business Solutions after COVID-19

Anton Lavrentyev spoke at  the RBC-TV online conference dedicated to anti-crisis solutions for busines after COVID 19.
 

Primer Capital to partner with Startup Rally 2020

1 April 2020

The application for participation in the Startup-Rally 2020 for pharmaceutical and healthcare projects is open.

Primer Capital to partner with Startup Rally 2020

The application for participation in the Startup-Rally 2020 for pharmaceutical and healthcare projects is open.
 

Data MATRIX EDC listed among the solutions recommended for the fight against Covid19

27 March 2020

The EDC platform, developed by Primer Capital's porfolio company, Data MATRIX, formed part of the list of recommended solutions in the official address to the Prime Minister of Russia.

Data MATRIX EDC listed among the solutions recommended for the fight against Covid19

The EDC platform, developed by Primer Capital's porfolio company, Data MATRIX, formed part of the list of recommended solutions in the official address to the Prime Minister of Russia.
 

Portfolio company offering free EDC platform to COVID19 researchers

20 March 2020

Primer Capital's porfolio unit, Data MATRIX announced today that it is to offer free Electronic Data Capture (EDC) for companies running COVID-19 trials.

Portfolio company offering free EDC platform to COVID19 researchers

Primer Capital's porfolio unit, Data MATRIX announced today that it is to offer free Electronic Data Capture (EDC) for companies running COVID-19 trials.
 

Primer Capital CEO speaking at the OpenTalks.AI

25 February 2020

February 21, Anton Lavrentyev, the CEO of Primer Capital participated in a panel discussion on Investing in AI within the OpenTalks.AI conference.

Primer Capital CEO speaking at the OpenTalks.AI

February 21, Anton Lavrentyev, the CEO of Primer Capital participated in a panel discussion on Investing in AI within the OpenTalks.AI conference.
 

6 lifehacks on how to work with a start-up

29 January 2020

Read another blog piece by Anton Lavrentev, Primer Capital CEO for VC.ro on 6 lifehacks on how to work with start-ups.

6 lifehacks on how to work with a start-up

Read another blog piece by Anton Lavrentev, Primer Capital CEO for VC.ro on 6 lifehacks on how to work with start-ups.
 

Primer Capital Founders featured in Forbes

3 December 2019

Primer Capital founders, Dmitry Sharov and Timur Avdeenko shared the story of the fund in a feature story by Forbes Russia.

Primer Capital Founders featured in Forbes

Primer Capital founders, Dmitry Sharov and Timur Avdeenko shared the story of the fund in a feature story by Forbes Russia.
 

Primer Capital at the III International Medical Investment Forum

28 November 2019

Primer Capital COO Elizaveta Rozhdestvenskaya spoke at the round table on Investing in Science during the III International Medical Investment Forum 2019.

Primer Capital at the III International Medical Investment Forum

Primer Capital COO Elizaveta Rozhdestvenskaya spoke at the round table on Investing in Science during the III International Medical Investment Forum 2019.
 

Primer Capital's porfolio project, raises €7M in addtion to its Series B

6 November 2019

Acticor Biotech, Primer Capital's portfolio unit, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million.

Primer Capital's porfolio project, raises €7M in addtion to its Series B

Acticor Biotech, Primer Capital's portfolio unit, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced that it has raised €7 million in addition to its Series B which is now completed at €22,3 million.
 

With luck it takes at least seven years for the product to enter the market

23 October 2019

In her interview for Rusbase Primer Capital COO Elizaveta Rozhdenstvenskaya shared her thoughts on the pharma and biotech startups and the overall venture market trends.

With luck it takes at least seven years for the product to enter the market

In her interview for Rusbase Primer Capital COO Elizaveta Rozhdenstvenskaya shared her thoughts on the pharma and biotech startups and the overall venture market trends.

Записи 1 - 10 of 61
First | Prev. | 1 2 3 4 5 | Next | Last